A Phase 1 Mass Balance Study of 14C‐Labeled Talazoparib in Patients With Advanced Solid Tumors
Adult
Aged, 80 and over
Male
Administration, Oral
Middle Aged
6. Clean water
3. Good health
Feces
03 medical and health sciences
0302 clinical medicine
Neoplasms
Humans
Phthalazines
Female
Carbon Radioisotopes
Aged
Half-Life
DOI:
10.1002/jcph.1415
Publication Date:
2019-04-09T16:54:43Z
AUTHORS (8)
ABSTRACT
Abstract This paper describes the pharmacokinetics (PK), mass balance, metabolic profiling, and safety of talazoparib after a single oral dose 14 C‐talazoparib in 6 patients with advanced solid tumors. Patients were aged ≥18 years, histologically confirmed tumor at screening. A 1‐mg solution supplemented 100 µCi C‐labeled was administered. Blood, urine, feces samples collected various time points analyzed for C radioactivity. Metabolic profiling identification also carried out. Mean recovery radioactivity 68.7% urine 19.7% feces. Talazoparib minimally metabolized. Renal excretion unchanged major route elimination, mean 54.6% administered dose, whereas fecal limited, 13.6% dose. No metabolites identified plasma, no that individually represented more than 10% recovered or The concentration‐time profiles talazoparib, total whole blood similar, median peak concentrations 30 minutes half‐life 89.8, 96.2, 77.6 hours, respectively. metabolized, renal elimination.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (8)
CITATIONS (17)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....